Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NK cell therapy (autologous)
- Development stage
- Unknown
- Lead developer
- Shining Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
NK Cell Therapy (Autologous) is an autologous cell therapy developed by Shining Biotech. The treatment involves the extraction, expansion, and activation of a patient's own natural killer (NK) cells, which are then re-infused to target and eliminate malignant cells. This therapy is approved in Taiwan under the Special Regulations for Medicinal Products for Treating Rare Diseases and for Regenerative Medicine (再生醫療施行細則). It is indicated for patients with Stage 1-3 solid cancers who have failed standard treatments, as well as for Stage 4 solid cancers including colorectal, esophageal, gastric, lung, liver, breast, prostate, renal cell carcinoma, and malignant glioma. Shining Biotech partners with several hospitals in Taiwan, including Chang Bing Show Chwan Memorial Hospital, Renji Hospital, Tung's Taichung MetroHarbor Hospital, and Taipei Mackay Memorial Hospital, for the administration of this therapy.
- Other names
- Autologous NK Cell Therapyautologous natural killer cell therapy
02
Targets
IgG Fc (Immunoglobulin G Fc region)NKG2DL (NKG2D ligand family)
Beyond the preview
Go deeper on NK cell therapy (autologous).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NK cell therapy (autologous).